Bounded definition
Vehicles and formulations that transport genome-editor components to a defined cell population or tissue.
What the cited work establishes
The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis.
The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
Claims: urn:maha:claim:genome-editor-delivery-systems
What remains a separate question
One liver-targeted formulation does not establish delivery to other tissues, repeat dosing, long-term safety, or a general delivery platform.
Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets.
Connected domain graph
Typed dependencies preserve publication state.
Only independently canonical records receive public links and relation statements. Draft graph topology remains private.
In-vivo genome-editing workflow
outbound connection · method
In-vivo editing depends on tissue exposure produced by a delivery system.
In-vivo genome-editing workflow
inbound connection · method
The in-vivo workflow depends on tissue-specific delivery and exposure.
Claim ledger
Every proposition keeps its own evidence state.
The cited phase 1 study reports systemic lipid-nanoparticle delivery of Cas9 mRNA and guide RNA to hepatocytes under a named investigational protocol.
- Scope
- The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
- Boundary
- One liver-targeted formulation does not establish delivery to other tissues, repeat dosing, long-term safety, or a general delivery platform.
- Uncertainty
- There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices.
- Replication
- This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.
Primary sources
Citation, locator, rights, and boundary travel together.
Source 1 · The New England Journal of Medicine
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Julian D. Gillmore, Ed Gane, Julian Taubel, Jingzhu Kao, et al.
- Exact locator
- Abstract; Methods; Results; Figures 1–3; supplementary protocol and statistical analysis.
- Establishes
- The phase 1 report describes systemic lipid-nanoparticle delivery of CRISPR components and early dose-cohort biomarker and safety observations in adults with transthyretin amyloidosis.
- Boundary
- Early biomarker and safety observations do not establish long-term clinical benefit, rare-event safety, or transfer to other tissues and targets.
- Rights basis
- citation with paraphrase · Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.
- Declared interests
- The study was funded by Intellia Therapeutics and Regeneron Pharmaceuticals; author relationships are disclosed.